Reema Wahdan-Alaswad, PhD

Publications

• Wahdan-Alaswad R, Harrell JC, Fan Z, Edgerton SM, Liu B, Thor AD. Metformin attenuates transforming growth factor beta (TGF-ß) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. Cell Cycle. 2016;15(8):1046-59. doi: 10.1080/15384101.2016.1152432. PMID: 26919310
• Checkley, AL, Rudolph MC, Wellberg EA, Giles E, Wahdan-Alaswad RS, Houck J, Edgerton S, Thor AD, Anderson SM, Schedin PS, MacLean PS. Organic cation transporter 2 positive mammary tumors accumulate metformin reducing tumor cell proinflammatory fatty acids and tumor growth independent of systemic metabolism. (Submitted to Molecular Cancer Therapeutics, In press as of 1-18-17).
• Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, Edgerton SM, Thor AD, Schedin P, Anderson SM, MacLean PS. Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo . Cancer Prev Res (Phila). 2017 Mar;10(3):198-207. PubMed PMID: 28154203
• Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer. 2017 Dec;8(5-6):269-285. PubMed PMID: 28741260
• Reema S Wahdan-Alaswad, Susan M Edgerton, Hiba S Salem, and Ann D Thor. Metformin Targets Cholesterol Biosynthesis Pathway, Gm1 Lipid Raft Stabilization, EGFR Signaling and Proliferation in Triple Negative Breast Cancers. Cancer Therapy & Oncol Int J. 2018; 9(3): 555765. DOI: 10.19080/CTOIJ.2018.09.555765.
• Wahdan-Alaswad RS, Edgerton SM, Salem HS, Thor AD. Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer. J Oncol Transl Res. 2018; 4: 129. PMID 29780974 doi:10.4172/2476-2261.1000129.
• Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2020 Oct 23. [Epub ahead of print] PubMed PMID: 33097494
• Wahdan-Alaswad RS and Thor AD. Metformin activity against breast cancer: mechanistic differences by molecular subtype and metabolic conditions. InTech Open Book Chapter Metformin. Feb 12, 2020. DOI: 10.5772/intechopen.91183.
• Wahdan-Alaswad RS, Liu B, Thor AD. Targeted Lapatinib Anti-HER2/ErbB2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem. Cancer Drug Resistance. 2020; 3:179-198. DOI:10.20517/cdr.2019.92.
• Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim HM, Tan AC, Finlay-Schultz J, Wellberg EA, Sartorius CA, Jacobsen BM, Haugen BR, Liu B, Thor AD. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 Jan 15;27(2):585-597. PubMed PMID: 33097494
• 20. Wahdan-Alaswad RS, Edgerton SM, Kim H, Tan AC, Haugen BR, Liu B, Thor AD. Thyroid Hormone Enhances Estrogen-mediated Proliferation and Cell Cycle Regulatory Pathways in Steroid Receptor-Positive Breast Cancer. EPub ahead of print. DOI 10.1080/15384101.2023.2249702 Accepted Aug 2023.